Iran has recently made remarkable strides in the field of regenerative medicine, climbing from the 12th to the 7th position globally. This leap is primarily attributed to the approval of six advanced therapy medicinal products (ATMPs), showcasing the nation’s growing influence and innovation in this vital sector.
A Surge in ATMP Approvals
In 2025, the global landscape of ATMPs saw a significant increase, with 148 products approved by twelve internationally recognized regulatory bodies. Among these, seven products originated from Iran, propelling the country into the top ten rankings in regenerative medicine. This achievement not only highlights Iran’s capabilities but also positions it as a key player in the international biotechnology arena.
Growth of Licensed Products
The Iranian year 1402, spanning from March 2023 to March 2024, witnessed a modest presence of just one licensed product in regenerative medicine. However, the current year has marked an impressive escalation, with seven licensed products introduced. These include advancements in cell therapy, tissue engineering, and chimeric antigen receptor (CAR) T-cell therapies, addressing a range of medical conditions such as vitiligo, graft-versus-host disease, cerebral palsy, burns, diabetic foot ulcers, arthritis, and B-cell acute lymphoblastic leukemia. The potential for these high-tech medical products to be exported further signifies Iran’s growing prowess in the biotechnology sector.
Advancements in Stem Cell Therapy
Iran’s advancements in stem cells and cell therapy have not gone unnoticed, as the country has ascended to the eighth position globally in this domain. Mostafa Qanei, an official from the Vice-Presidency for Science and Technology, emphasized this progress during a recent press conference. He noted the remarkable increase from one to five cell therapy products on the market and underscored the nation’s ambition to break into the top five worldwide. This aspiration aims to ensure that patients can access cutting-edge treatments domestically, reducing the necessity for medical travel abroad.
Future Projects on the Horizon
Looking forward, Saeed Sarkar, another official from the Vice-Presidency for Science and Technology, outlined an ambitious agenda for the current Iranian year, which concludes in March 2026. This agenda includes twenty innovative technological projects aimed at improving health outcomes. Notable initiatives involve the production of drugs for spinal muscular atrophy and the development of early detection kits for digestive cancers. These projects not only promise to enhance healthcare but are also projected to save around $40 million in foreign currency.
Enhancing Medicinal Plant Efficacy
Iran is also focusing on the integration of traditional medicine with modern technology. One key objective is to boost the effectiveness of medicinal plants through advanced methods like nanotechnology. For instance, researchers are developing nanocapsules loaded with curcumin to improve absorption. Additionally, clinical trials are underway to substantiate the effects of traditional remedies, with the findings intended for verification by the health ministry.
The Role of Artificial Intelligence in Healthcare
As the health sector evolves, the incorporation of artificial intelligence (AI) is becoming increasingly prominent. Sarkar discussed the deployment of AI tools in critical areas such as radiology and pathology. These technologies aim to enhance diagnostic accuracy, reduce costs, and expand public access to healthcare services. The potential of AI to expedite clinical decision-making while mitigating risks represents a significant advancement in medical practice.
Conclusion
Iran’s recent achievements in regenerative medicine signify a transformative phase for the country, marking its emergence as a key player in the global biotechnology landscape. With a focus on innovation, traditional medicine integration, and the adoption of advanced technologies, Iran is well-positioned to continue its ascent. As the nation strives for even greater accomplishments in healthcare, the world will undoubtedly be watching closely.
- Takeaway 1: Iran has moved from 12th to 7th globally in regenerative medicine due to six new ATMP approvals.
-
Takeaway 2: The growth of licensed products has surged from one to seven in just one year.
-
Takeaway 3: Future projects aim to produce innovative drugs and save significant foreign currency.
-
Takeaway 4: Advances in AI are set to enhance diagnostic accuracy and expand healthcare access.
-
Takeaway 5: Iran is integrating nanotechnology with traditional medicine to improve treatment efficacy.
Read more → www.tehrantimes.com